INT165492

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.20
First Reported 2009
Last Reported 2010
Negated 1
Speculated 2
Reported most in Body
Documents 1
Total Number 6
Disease Relevance 6.76
Pain Relevance 0.68

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (CX3CL1) extracellular region (CX3CL1) plasma membrane (CX3CL1)
cytoplasm (CX3CL1)
Anatomy Link Frequency
coronary artery 2
plasma 2
CX3CL1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 188 97.08 Very High Very High Very High
chemokine 72 78.56 Quite High
cytokine 25 77.96 Quite High
Angina 5 44.72 Quite Low
Pain 3 10.00 Low Low
antagonist 5 5.00 Very Low Very Low Very Low
Inflammatory response 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hyperlipidemia 105 99.98 Very High Very High Very High
Diabetes Mellitus-type I 120 99.84 Very High Very High Very High
Coronary Artery Disease 225 99.48 Very High Very High Very High
Cardiovascular Disease 15 99.28 Very High Very High Very High
Atherosclerosis 90 97.16 Very High Very High Very High
INFLAMMATION 183 97.08 Very High Very High Very High
Diabetes Mellitus 125 93.84 High High
Acute Coronary Syndrome 5 82.40 Quite High
Diabetic Nephropathy 25 80.12 Quite High
Adhesions 61 77.12 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We observed a dose-dependent reduction in fractalkine production (Figure 3).


Negative_regulation (reduction) of Gene_expression (production) of fractalkine
1) Confidence 0.20 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2762434 Disease Relevance 1.20 Pain Relevance 0.05
Fractalkine levels have only been rarely determined in patients; however, it has been shown that Alzheimer patients express enhanced fractalkine levels, correlating with the Mini-Mental State Examination (MMSE) score.20 Another study also reported that fractalkine levels are enhanced in WegenerÂ’s granulomatosis.21 In patients with coronary artery disease fractalkine plasma levels were enhanced and then reduced after statin therapy.22 When CX3CR1 genotypes were analyzed in patients with acute coronary syndromes and healthy controls, CX3CR1-I249 heterozygosity was associated with a markedly reduced risk of acute coronary events, independent of established coronary risk factors such as smoking or diabetes.23,24
Spec (determined) Negative_regulation (determined) of Gene_expression (levels) of Fractalkine in plasma associated with acute coronary syndrome, nicotine addiction, diabetes mellitus and cardiovascular disease
2) Confidence 0.20 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2762434 Disease Relevance 0.74 Pain Relevance 0.21
Indeed, fractalkine levels were reduced in patients with coronary artery disease after a six-week statin treatment.22 Thus, rehabilitation may normalize levels of fractalkine.
Negative_regulation (reduced) of Gene_expression (levels) of fractalkine in coronary artery associated with cardiovascular disease
3) Confidence 0.20 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2762434 Disease Relevance 1.33 Pain Relevance 0.15
Postprandial hyperlipemia does not reduce fractalkine levels in IDDM and CHD patients
Neg (not) Negative_regulation (reduce) of Gene_expression (levels) of fractalkine associated with diabetes mellitus-type i, coronary artery disease and hyperlipidemia
4) Confidence 0.20 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2762434 Disease Relevance 1.88 Pain Relevance 0.12
Postprandial hyperlipemia reduced the fractalkine levels in control subjects and in vessel wall cells in vitro, whereas postprandial hyperlipemia did not result in significantly different fractalkine levels in diabetic and CHF patients according to ANOVA.
Negative_regulation (reduced) of Gene_expression (levels) of fractalkine associated with diabetes mellitus and hyperlipidemia
5) Confidence 0.20 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2762434 Disease Relevance 1.51 Pain Relevance 0.15
AREAS COVERED IN THIS REVIEW: We performed a Medline/PubMed search to detect all published studies that explored the role of fractalkine and CX3CR1 and the possibilities of therapeutic intervention in the fractalkine/CX3CR1 axis in a wide range of clinical disorders, using CX3CR1 blocking antibodies, different fractalkine antagonists, CX3CR1 depletion or transfection of fractalkine expression vectors.
Spec (possibilities) Negative_regulation (explored) of Gene_expression (role) of fractalkine
6) Confidence 0.15 Published 2010 Journal Expert Opin. Ther. Targets Section Body Doc Link 20055718 Disease Relevance 0.09 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox